XOMA’s (XOMA) Buy Rating Reaffirmed at HC Wainwright

XOMA (NASDAQ:XOMAGet Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $74.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 200.20% from the stock’s current price.

Other equities analysts also recently issued reports about the company. SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They issued an “outperform” rating and a $40.00 price target for the company. Leerink Partnrs restated an “outperform” rating on shares of XOMA in a report on Monday, April 29th.

Read Our Latest Research Report on XOMA

XOMA Price Performance

XOMA stock opened at $24.65 on Tuesday. The company has a current ratio of 9.45, a quick ratio of 9.45 and a debt-to-equity ratio of 1.39. The company has a fifty day simple moving average of $24.78 and a 200-day simple moving average of $23.51. The stock has a market cap of $286.93 million, a P/E ratio of -6.29 and a beta of 0.93. XOMA has a 12-month low of $13.48 and a 12-month high of $27.36.

XOMA (NASDAQ:XOMAGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). The business had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.96 million. XOMA had a negative return on equity of 26.00% and a negative net margin of 705.23%. Equities analysts expect that XOMA will post -1.76 EPS for the current fiscal year.

Institutional Trading of XOMA

An institutional investor recently bought a new position in XOMA stock. Price T Rowe Associates Inc. MD acquired a new stake in XOMA Co. (NASDAQ:XOMAFree Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 8,778 shares of the biotechnology company’s stock, valued at approximately $212,000. Price T Rowe Associates Inc. MD owned about 0.08% of XOMA at the end of the most recent quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Further Reading

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.